Endocrine Research Updates
For Medical Professionals
Preliminary data for investigational ertugliflozin suggests favorable outcomes for people with recalcitrant type 2 diabetes despite improvements in physical activity and diet.
Total thyroidectomy is underutilized but promises the best outcomes for Grave's disease, but the risk of serious complications is high, necessitating referral to a highly trained surgeon.
As regulators of metabolism, thyroid hormones help explain why some individuals lose weight while others don't on any given weight-loss regime.
Clinical support for puberty suppression often improves emotional wellbeing during a time of sexual uncertainty and may ease feelings of gender incongruence.
Examining the effects of an endogenous cannabinoid uncovered a dual response in the pathways that regulate inflammatory response in the gut.
Injections with a monoclonal antibody therapy, Eylea, provided superior results and outperformed laser surgery for treatment of diabetic retinopathy.
TYMLOS (abaloparatide), a new bone-building anabolic therapeutic agent for high fracture risk, older women, including those with diabetes or thyroid disease, gains Food and Drug Administration approval.
Participating in a structured lifestyle program with regularly attended sessions promotes improved eating habits and commitment to exercise forestallling diabetes risks.
To achieve long-term remission, clinicians should anticipate the need for additional treatment following surgery for Cushing's disease in 25% of patients.
In African Americans, men, and other minorities, ketosis-prone diabetes appears more consistent with type 2 diabetes but responds to insulin as if type 1 diabetes.
iSage Rx is the only prescription-required mobile platform designed to guide patients in basal insulin titration and health self-management.
Early, aggressive treatment for insulin resistance (prediabetes) in middle-aged individuals with cardiovascular disease greatly reduces the risk of advancing cognitive function.
The move to a more goal-oriented, patient-centered approach to osteoporosis treatment was presented during the Clinical Osteoporosis 2017 conference.
From PROMIS, genetic variants that were exclusively associated with apoprotein(a) size and concentration provide further indication that lowering the lipoprotein(a) concentration may be a strategy to reduce cardiovascular disease risk.
Evaluating patients with an endocrine-related disorder, particularly those under age 40 who present with high blood pressure, is critical to ensure treatment is provided to life-saving effect.
Papillary thyroid cancer is the most common form, and highly curable, but up to 20% of cases have a high rate of rapid growth and recurrence; genetic testing can improve their detection with greater chance for effective treatment.
Compelling data supports achieving a very low LDL-Cholesterol with combined statin-evolocumab therapy to reduce further risk of cardiovascular events, which presents important implications for people with diabetes.
Among children with a diagnosis of diabetes, an estimated 1-in-4 cases of diabetic retinopathy may be going undetected for years, risking vision loss, based on current screening guidelines.
While diet, exercise, and behavior modification are key components of weight management, several physiological mechanisms act to preserve excess body weight, necessitating consideration of and conversations with the patient.
Innovations in treatment over the past 15 years for people with diabetes who are most at risk of blindness
